VANDA PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
VANDA PHARMACEUTICALS INC. - More news...
VANDA PHARMACEUTICALS INC. - More news...
- Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
- Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
- Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
- Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
- Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
- Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
- FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
- Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
- Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
- Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
- Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
- Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
- Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
- Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
- Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
- Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
- Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
- Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
- Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
- Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
- Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
- Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
- Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
- Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
